Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

Ruud M A van de Wal; Pim van der Harst; Wim B M Gerritsen; Fal van der Horst; Thijs H W Plokker; Ron T Gansevoort; Wiek H van Gilst; Adriaan A Voors

doi:10.3317/jraas.2007.029

Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

Ruud M A van de Wal, Pim van der Harst, Wim B M Gerritsen, Fal van der Horst, Thijs H W Plokker, Ron T Gansevoort, Wiek H van Gilst, Adriaan A Voors

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

INTRODUCTION: Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition.

MATERIAL AND METHODS: In a placebo-controlled randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.

RESULTS: Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871). Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4+/-2.4 vs. 1.8+/-1.3 mg/24 hours, p<0.001, respectively). However, fosinopril treatment failed to significantly change plasma MMP-9 levels compared to placebo (-0.47+/-7.68 vs. 0.06+/-9.20, p=0.646, respectively). In addition, the change in UAE was not related with change in MMP-9 levels.

CONCLUSION: The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.

Original language	English
Pages (from-to)	177-80
Number of pages	4
Journal	Journal of the renin-angiotensin-aldosterone system
Volume	8
Issue number	4
DOIs	https://doi.org/10.3317/jraas.2007.029
Publication status	Published - Dec 2007
Externally published	Yes

Keywords

Albuminuria/blood
Angiotensin-Converting Enzyme Inhibitors/therapeutic use
Diabetes Mellitus/blood
Female
Fosinopril/therapeutic use
Humans
Male
Matrix Metalloproteinase 9/blood
Middle Aged
Placebos

Access to Document

10.3317/jraas.2007.029

Cite this

van de Wal, R. M. A., van der Harst, P., Gerritsen, W. B. M., van der Horst, F., Plokker, T. H. W., Gansevoort, R. T., van Gilst, W. H., & Voors, A. A. (2007). Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the renin-angiotensin-aldosterone system, 8(4), 177-80. https://doi.org/10.3317/jraas.2007.029

@article{7d598b4f603e48bda170f20ed3ef1dbf,

title = "Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects",

abstract = "INTRODUCTION: Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition.MATERIAL AND METHODS: In a placebo-controlled randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.RESULTS: Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871). Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4+/-2.4 vs. 1.8+/-1.3 mg/24 hours, p<0.001, respectively). However, fosinopril treatment failed to significantly change plasma MMP-9 levels compared to placebo (-0.47+/-7.68 vs. 0.06+/-9.20, p=0.646, respectively). In addition, the change in UAE was not related with change in MMP-9 levels.CONCLUSION: The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.",

keywords = "Albuminuria/blood, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Diabetes Mellitus/blood, Female, Fosinopril/therapeutic use, Humans, Male, Matrix Metalloproteinase 9/blood, Middle Aged, Placebos",

author = "{van de Wal}, {Ruud M A} and {van der Harst}, Pim and Gerritsen, {Wim B M} and {van der Horst}, Fal and Plokker, {Thijs H W} and Gansevoort, {Ron T} and {van Gilst}, {Wiek H} and Voors, {Adriaan A}",

year = "2007",

month = dec,

doi = "10.3317/jraas.2007.029",

language = "English",

volume = "8",

pages = "177--80",

journal = "Journal of the renin-angiotensin-aldosterone system",

issn = "1470-3203",

publisher = "SAGE Publications Ltd",

number = "4",

}

van de Wal, RMA, van der Harst, P, Gerritsen, WBM, van der Horst, F, Plokker, THW, Gansevoort, RT, van Gilst, WH & Voors, AA 2007, 'Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects', Journal of the renin-angiotensin-aldosterone system, vol. 8, no. 4, pp. 177-80. https://doi.org/10.3317/jraas.2007.029

Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. / van de Wal, Ruud M A; van der Harst, Pim; Gerritsen, Wim B M et al.
In: Journal of the renin-angiotensin-aldosterone system, Vol. 8, No. 4, 12.2007, p. 177-80.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

AU - van de Wal, Ruud M A

AU - van der Harst, Pim

AU - Gerritsen, Wim B M

AU - van der Horst, Fal

AU - Plokker, Thijs H W

AU - Gansevoort, Ron T

AU - van Gilst, Wiek H

AU - Voors, Adriaan A

PY - 2007/12

Y1 - 2007/12

N2 - INTRODUCTION: Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition.MATERIAL AND METHODS: In a placebo-controlled randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.RESULTS: Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871). Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4+/-2.4 vs. 1.8+/-1.3 mg/24 hours, p<0.001, respectively). However, fosinopril treatment failed to significantly change plasma MMP-9 levels compared to placebo (-0.47+/-7.68 vs. 0.06+/-9.20, p=0.646, respectively). In addition, the change in UAE was not related with change in MMP-9 levels.CONCLUSION: The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.

AB - INTRODUCTION: Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition.MATERIAL AND METHODS: In a placebo-controlled randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.RESULTS: Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871). Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4+/-2.4 vs. 1.8+/-1.3 mg/24 hours, p<0.001, respectively). However, fosinopril treatment failed to significantly change plasma MMP-9 levels compared to placebo (-0.47+/-7.68 vs. 0.06+/-9.20, p=0.646, respectively). In addition, the change in UAE was not related with change in MMP-9 levels.CONCLUSION: The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.

KW - Albuminuria/blood

KW - Angiotensin-Converting Enzyme Inhibitors/therapeutic use

KW - Diabetes Mellitus/blood

KW - Female

KW - Fosinopril/therapeutic use

KW - Humans

KW - Male

KW - Matrix Metalloproteinase 9/blood

KW - Middle Aged

KW - Placebos

U2 - 10.3317/jraas.2007.029

DO - 10.3317/jraas.2007.029

M3 - Article

C2 - 18205096

SN - 1470-3203

VL - 8

SP - 177

EP - 180

JO - Journal of the renin-angiotensin-aldosterone system

JF - Journal of the renin-angiotensin-aldosterone system

IS - 4

ER -

Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

Abstract

Keywords

Access to Document

Fingerprint

Cite this